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In the previous issue of *Critical Care*, Dr Flores and colleagues travel down a familiar path \[[@B1]\]. Throughout the history of medicine, physicians have wondered how to account for the fact that individuals may respond so differently to similar illnesses. Indeed, some of these relationships are obvious -- patients who do not receive antibiotics in a timely fashion may progress rapidly from infection to septic shock \[[@B2]\]; an older patient may be more likely to die than a younger, healthier patient with the same illness \[[@B3]\]. Many a physician, however, has been left to wonder why, given two relatively similar patients with community-acquired pneumonia, one patient may recover quickly with a standard course of antibiotics while another patient develops catastrophic acute lung injury with its attendant profound hypoxemia, multiorgan failure, and high mortality rate.

The difference, of course, has long been thought to be in the genes. That is, the disease phenotype of the patient results from the sum of the complex interactions between the environment and the patient\'s genotype \[[@B4]\]. We are now at the beginning of the second decade of the effort to better define the role played by genetic variation in the pathogenesis of acute lung injury and its most severe form, acute respiratory distress syndrome \[[@B1]\].

The reasons for conducting such investigations are compelling. By establishing the importance of genetic variation in determining the final disease phenotype, it may be possible to work backwards and identify the proteins that play a more important role in disease pathogenesis. This might improve our understanding of acute lung injury/acute respiratory distress syndrome disease processes as well as generate targets for therapeutic intervention. From the standpoint of the clinician, knowing how the patient\'s genotype will affect the course of their illness might enable more accurate prognostic assessment, or may even allow targeted therapeutic interventions based on how the patient\'s genotype predicts they will respond \[[@B5]\].

As Flores and colleagues note, however, the road to these anticipated outcomes has been bumpy. In their comprehensive exploration of the state of the literature, the authors evaluated 29 original research studies that reported positive associations between genetic variants and an altered level of risk of developing acute lung injury/acute respiratory distress syndrome, or positive associations with clinical outcomes \[[@B1]\]. They then sought to evaluate the quality of these studies according to the recommendations of an expert panel \[[@B6]\]. This panel aimed to address a major issue that has plagued genetic association studies: replication validity. Despite a growing number of reported positive genotype--phenotype associations across a variety of different diseases, a substantial proportion of these associations lose significance when tested in different patient populations, casting doubt on whether the association truly exists or merely represents a chance finding \[[@B7]\]. As part of this group\'s recommendations, they developed a list of consensus criteria for evaluating the quality of studies that report novel associations. This is relevant because the use of less robust methodology in initial studies may hamper efforts to replicate their results \[[@B8]\]. The panel\'s criteria address a number of study design elements, including power and sample size, precise definition of phenotypes, careful steps to reduce confounding, appropriate selection of statistical methods, and close attention to quality control.

Using elements of these criteria as a guide, Flores and colleagues discovered a few notable trends in the published literature \[[@B1]\]. Most of the published studies reported positive associations, in a total of 16 genes. Of these positive associations, less than one-half were replicated in additional populations. It is impossible to know how many of the unreplicated results were not published because the associations were found to be negative, or how many additional genes showed negative associations that were not published. Many studies had disappointing sample sizes, with a median of around 100 to 200 patients depending on the study design. In addition, most studies did not report power calculations. Flores and colleagues also point out heterogeneity in the selection of a control group for case--control studies, with a plurality of the studies selecting healthy subjects or population-based control individuals.

These findings present a mixed picture -- owing to the number of studies with small sample sizes, a lack of replication studies, absence of power calculations, and an unknown number of unpublished negative studies, it is possible that many of these associations were found merely due to chance. The choice of control groups in some studies is also somewhat troubling. If the goal is to study the impact of genotype on the risk of developing lung injury, it seems counterintuitive to select healthy patients or population-based control individuals as the comparison group since these patients may in fact be genetically susceptible and only require an appropriate external stimulus to develop the disease.

Despite these potential flaws in published studies, the authors also point to successes in the literature that can be built upon -- they suggest a need for studies with improved initial quality (large sample sizes with adequate power, selection of appropriate control groups, use of functional surrogates to support associations with disease phenotype) as well as the need for replication of initial findings. Future studies should also employ newer technologies and strategies such as large-scale multigene association studies, gene expression studies \[[@B9]\], and biomarker/proteomic technologies \[[@B10]\] both for identification of novel candidate genes and to provide additional data that support the relevance of reported associations. A concerted effort by researchers and journal editors should also be made to ensure that negative initial and replication studies are published to reduce the impact of publication bias. Finally, further studies in different racial populations are needed.

A decade into the course of this work, we have taken only small steps towards the goal. As Flores and colleagues show, however, the foundation has been laid for ultimately answering the crucial question posed by physicians -- can we take what we have learned about genotypes and apply it to the care of the patient in front of us?
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